Leuphasyl: A Literature Course on Pentapeptide-18

This six-module course summarises the peer-reviewed literature that mentions Leuphasyl — the trade name most often associated with the cosmetic ingredient pentapeptide-18 — and the closely related peptide chemistry that informs how the molecule has been described. Each module ends with an explicit statement of what the evidence cannot support. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medical condition, a product, or an ingredient.

Module 1: What Leuphasyl Is and How It Has Been Studied

Definition and class

Leuphasyl is a commercial designation used for a short synthetic peptide whose cosmetic ingredient (INCI) name is Pentapeptide-18. Structurally it belongs to the family of enkephalin-related peptides: short sequences modelled on the endogenous opioid pentapeptide Leu-enkephalin, typically with a D-amino-acid substitution in the second position to slow enzymatic breakdown. It is not a hormone, not a growth factor, and not a botulinum-type protein, although marketing language in the cosmetics sector has often grouped it with "muscle-relaxing" topical ingredients.

Origin and forms encountered in the literature

The published work that names the molecule directly is recent and biophysical rather than clinical. A 2026 computational and spectroscopic paper examined pentapeptide-18 as an anti-aging candidate, and the researchers reported spectroscopic characterization together with molecular interaction analysis of the peptide (PMID 41722287). Separately, a 2024 formulation study optimized and characterized solid lipid nanoparticles co-loaded with retinol and pentapeptide-18 and discussed their cosmetic application (PMID 39337562). A companion 2024 paper described retinol- and oligopeptide-loaded lipid nanocarriers as a raw material intended for anti-acne and anti-aging formulation work (PMID 39459512).

Across that record, the forms in which the peptide appears are: a synthetic peptide in solution used for biophysical measurement (PMID 41722287), and a peptide encapsulated in or combined with lipid-based carriers intended for topical vehicles (PMID 39337562, PMID 39459512). Peptide chemistry papers on the wider enkephalin-like family supply the pharmacological context: a 2021 medicinal-chemistry study synthesised C-terminal modified enkephalin-like tetrapeptides and researchers reported enhanced affinities at the kappa opioid receptor and at monoamine transporters (PMID 34798381).

Limits of the evidence in Module 1

• The verified record contains no randomised controlled trial, no split-face clinical study, and no long-term human cohort naming Leuphasyl or pentapeptide-18.
• Identity information such as sequence and ingredient nomenclature comes from chemical and regulatory naming conventions, not from a clinical outcome study.
• Where a paper describes an "oligopeptide" rather than naming pentapeptide-18 explicitly, its findings cannot be transferred to Leuphasyl without that identification (PMID 39459512).

Module 2: Mechanism as Described in the Literature

The enkephalin-receptor framing

The mechanistic story usually attached to Leuphasyl is an opioid-receptor framing: enkephalin-like peptides engage opioid receptors, and receptor engagement at neuromuscular or neuronal interfaces has been proposed to modulate signalling that contributes to repeated muscle contraction. The verified literature supports the first half of that chain only in the broader peptide family. In the 2021 study, researchers modified the C-terminus of enkephalin-like tetrapeptides and reported enhanced binding affinities at the kappa opioid receptor and at monoamine transporters, demonstrating that small structural changes in this family measurably shift receptor interaction (PMID 34798381).

That paper is about analog design, not about Leuphasyl, and it did not test a cosmetic endpoint (PMID 34798381). It is included here because it establishes what kind of evidence a receptor-level mechanism claim would require: measured affinity values in a defined assay system.

Molecular interaction and structure descriptions

For pentapeptide-18 itself, the closest mechanistic work is biophysical. The 2026 study combined spectroscopic characterization with molecular interaction analysis and researchers positioned the peptide as an anti-aging candidate on the basis of those analyses (PMID 41722287). Analyses of that type describe how a peptide behaves in solution and how it is predicted to associate with a target surface; they are hypothesis-generating and do not measure a change in skin or muscle.

Stereochemistry matters: the D-tyrosine observation

Enkephalin-type peptides carry an N-terminal tyrosine, and stereochemistry at that residue has been studied as a determinant of activity. In a 2020 report, researchers described that adding D-tyrosine conferred an anti-melanogenic effect on cosmetic peptides, an activity distinct from the muscle-signalling framing usually cited for this ingredient class (PMID 31937863). The study is useful as a reminder that a single stereochemical change in a cosmetic peptide can introduce an entirely different reported activity (PMID 31937863).

Limits of the evidence in Module 2

• No verified paper measured pentapeptide-18 binding at an opioid receptor; the receptor data available concern modified enkephalin-like tetrapeptides, not Leuphasyl (PMID 34798381).
• No verified paper measured neuromuscular activity, muscle contraction, or facial movement after application of the peptide.
• Biophysical and molecular-interaction analyses describe predicted or in-solution behaviour, not tissue-level outcomes (PMID 41722287).

Module 3: Reported Outcomes by Study

The table below summarises what each verified paper examined and what researchers reported at abstract level. No dose, concentration or treatment duration is listed, because the verified abstracts reviewed for this course do not supply human dosing figures that could be reported accurately.

Reading the outcome pattern

Two of the five papers are formulation-science studies whose endpoints are physicochemical rather than clinical; the outcome measured is how well a carrier holds and presents the active, not what happens to a wrinkle (PMID 39337562, PMID 39459512). One is a biophysical characterization of the named peptide (PMID 41722287). The remaining two examine peptide analogs and report activities — anti-melanogenic effect and receptor affinity — that belong to the analogs tested rather than to Leuphasyl as sold (PMID 31937863, PMID 34798381).

A further complication for interpretation is co-formulation. In both nanoparticle papers the peptide was studied alongside retinol, a compound with its own extensively described dermatological activity, so any formulation-level performance cannot be attributed to the peptide alone (PMID 39337562, PMID 39459512).

Limits of the evidence in Module 3

• No verified study reported a measured change in wrinkle depth, expression-line severity, skin elasticity or photographic grading in human participants.
• No verified study compared the peptide against a placebo vehicle in people.
• Because the peptide was co-formulated with retinol in the delivery studies, single-ingredient attribution is not available (PMID 39337562).

Module 4: Leuphasyl Side Effects: What Studies Report

This module reports only what the verified papers contain. The two lipid-carrier papers were designed around formulation optimization, characterization and raw-material performance, and their abstracts did not present adverse-event tables, irritation scoring, sensitisation results or dropout data from human users (PMID 39337562, PMID 39459512). The biophysical characterization of pentapeptide-18 likewise addressed structure and molecular interaction rather than tolerability endpoints (PMID 41722287).

The analog papers report activity, not safety, in the sense a clinician would use the word: the 2020 study described an added anti-melanogenic effect after D-tyrosine substitution, which is an activity finding rather than an adverse-event finding (PMID 31937863), and the 2021 chemistry study reported enhanced kappa opioid receptor and monoamine transporter affinities for modified tetrapeptides without characterising in-use tolerability (PMID 34798381).

Two general observations follow from that pattern. First, an absence of reported adverse events in studies that never collected adverse-event data is not evidence of tolerability. Second, because receptor-level activity has been demonstrated for structurally related peptides (PMID 34798381), the theoretical safety questions for this family — systemic exposure, receptor cross-reactivity — are questions the verified record simply has not addressed.

Limits of the evidence in Module 4

• No verified paper reported irritation, erythema, contact dermatitis, allergy or systemic adverse events for pentapeptide-18 in humans.
• No verified paper conducted a dedicated toxicology or repeat-insult patch-test programme.
• Any statement about how well the ingredient is tolerated in real-world cosmetic use falls outside the verified literature reviewed here.

Module 5: Pharmacokinetics Where Data Exist

There is no human pharmacokinetic dataset for Leuphasyl in the verified record: no absorption curve, no plasma concentration measurement, no half-life, no clearance figure, and no bioavailability estimate. What exists instead is delivery-system science, which addresses the step before pharmacokinetics — whether a carrier can hold a peptide and present it at a surface.

The 2024 solid lipid nanoparticle study optimized and characterized a carrier incorporating retinol and pentapeptide-18, work that speaks to encapsulation and physical stability rather than to systemic disposition (PMID 39337562). The related 2024 lipid-nanocarrier paper evaluated retinol- and oligopeptide-loaded carriers as a raw material for topical anti-acne and anti-aging formulations, again a formulation-performance question (PMID 39459512).

Structural stability is the one pharmacokinetically relevant theme the analog literature touches. In the 2021 study, researchers modified the C-terminus of enkephalin-like tetrapeptides and reported enhanced receptor and transporter affinities, illustrating that terminal modification is a standard strategy in this family for tuning molecular properties (PMID 34798381). D-amino-acid substitution, discussed in the cosmetic-peptide context by the 2020 report on D-tyrosine, is a parallel strategy whose activity consequences researchers documented (PMID 31937863).

Limits of the evidence in Module 5

• No verified study measured skin permeation, dermal retention or systemic uptake of pentapeptide-18 in human skin.
• Carrier characterization data describe the vehicle, not the fate of the peptide in tissue (PMID 39337562).
• Half-life and metabolic-stability numbers for Leuphasyl are not present in the verified literature and are therefore not stated on this page.

Module 6: Regulatory Status, Stated Factually

Cosmetic ingredient status

Pentapeptide-18 is used as a cosmetic ingredient and carries an INCI name, which is a nomenclature standard rather than an approval. In the United States, cosmetic products and most cosmetic ingredients are not subject to premarket FDA approval; colour additives are the principal exception. Under the Modernization of Cosmetics Regulation Act (MoCRA), responsible persons must register facilities, list products and ingredients, and hold records substantiating product safety. In the European Union, cosmetic ingredients are governed by Regulation (EC) No 1223/2009, which requires a safety assessment and a product information file. None of this constitutes a therapeutic approval, and no verified paper in this course describes an approved drug product containing pentapeptide-18.

Research-use-only material

Synthetic peptides, including cosmetic-sequence peptides, are also distributed as research-use-only (RUO) chemicals. RUO labelling signals that the material is intended for laboratory investigation and has not been manufactured or reviewed for human administration; RUO status is not a quality claim and not an authorisation for human use.

Compounding

In the United States, pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act generally requires that a bulk drug substance be a component of an FDA-approved drug, appear in an applicable USP or NF monograph, or appear on the relevant FDA bulk drug substances list. A cosmetic-ingredient peptide that meets none of those criteria is not eligible for compounding into a drug product on that basis. This is general regulatory information, not legal advice.

Limits of the evidence in Module 6

• Regulatory categories describe what is permitted or required in commerce; they say nothing about efficacy, and no verified study in this course examined a regulatory endpoint.
• Ingredient nomenclature and cosmetic listing status do not imply that a clinical benefit has been demonstrated (PMID 41722287).
• Requirements differ by jurisdiction and change over time; primary regulatory texts remain the authority.

What the Studies Did Not Test

Read as a set, the verified literature on Leuphasyl is early-stage and formulation-heavy. The following questions were not answered by any of the papers cited here:

1. Clinical efficacy. No controlled human trial measured wrinkle, expression-line or elasticity outcomes for pentapeptide-18 (PMID 41722287).
2. Direct receptor pharmacology of the named peptide. The available affinity data concern modified enkephalin-like tetrapeptides (PMID 34798381).
3. Single-ingredient attribution. The delivery studies co-loaded retinol with the peptide, so contributions cannot be separated (PMID 39337562, PMID 39459512).
4. Adverse events and tolerability. No verified paper collected human safety endpoints.
5. Pharmacokinetics. No absorption, distribution, metabolism or excretion data were reported for the peptide.
6. Comparative effectiveness. No verified study compared the peptide with another cosmetic peptide, with retinoids alone, or with an injectable neuromodulator.
7. Duration. No verified study followed any outcome over months or years.

Where a marketing claim goes beyond those boundaries, the supporting evidence is not in the verified literature summarised here. Questions about whether any product or ingredient is appropriate for an individual belong with a licensed physician or dermatologist.

References

• Pentapeptide-18 as an anti-aging candidate: Spectroscopic characterization and molecular interaction analysis (Computational Biology and Chemistry, 2026)
• Solid Lipid Nanoparticles Incorporated with Retinol and Pentapeptide-18—Optimization, Characterization, and Cosmetic Application (International Journal of Molecular Sciences, 2024)
• Retinol and Oligopeptide-Loaded Lipid Nanocarriers as Effective Raw Material in Anti-Acne and Anti-Aging Therapies (Life, 2024)
• C-terminal modified Enkephalin-like tetrapeptides with enhanced affinities at the kappa opioid receptor and monoamine transporters (Bioorganic & Medicinal Chemistry, 2021)
• D-tyrosine adds an anti-melanogenic effect to cosmetic peptides (Scientific Reports, 2020)